RxDoctor Payments Data

Apoorva Vashi, MD

Urology · Jacksonville, FLNPI 1588705354

Payments from drug & device makers

$4,037in general payments, 2019–2025

Across 116 payments — averaging $34.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$955
  • Pfizer$597
  • Neotract Inc.$547
  • Dornier Medtech America, Inc$227
  • Teleflex LLC$225
  • Procept Biorobotics Corporation$175
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,037 in reported general payments places this provider in the 45th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$389,602
Medicare patients
1,134
Services billed
9,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron166$122,181
GemtesaVibegron12$13,832
Tamsulosin Hcl899$13,576
ElmironPentosan Polysulfate Sodium11$11,214
Finasteride705$10,049
VesicareSolifenacin Succinate13$5,046
Oxybutynin Chloride ErOxybutynin Chloride161$3,381
Silodosin22$2,329
Solifenacin Succinate62$2,286
Alfuzosin Hcl ErAlfuzosin Hcl64$1,595
Potassium Citrate ErPotassium Citrate17$1,499
Trimethoprim26$930
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$691
NitrofurantoinNitrofurantoin Macrocrystal18$406
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim105$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Vesicare$116$127,227179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 935 urology providers in Florida.

Other urology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →